This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Natrajan, R. Articles by Knowles, M. A. Search for Related Content PubMed PubMed Citation Articles by Natrajan, R. Articles by Knowles, M. A.

High-Resolution Deletion Mapping of 15q13.2-q21.1 in Transitional Cell Carcinoma of the Bladder

Division of Cancer Medicine Research, Cancer Research UK Clinical Centre, St. James’s University Hospital, Leeds, United Kingdom

Deletions found in several types of human tumor, including carcinomas of the colorectum, breast, and lung, suggest the presence of a potential tumor suppressor gene(s) on chromosome 15. Common regions of deletion in these tumors are at 15q15 and 15q21. Here, we have analyzed loss of heterozygosity (LOH) on chromosome 15 to ascertain its potential involvement in the development and progression of transitional cell carcinoma (TCC) of the bladder. A panel of 26 polymorphic markers, spanning 15q12–15q22, were used to map regions of LOH in 51 TCCs. LOH was found for at least one marker in the region 15q14–15q15.3 in 20 of 51 (39%) tumors. Deletion mapping defined two minimum regions of deletion: a distal region between the markers D15S514 and D15S537 at 15q15.1–15q15.3 (estimated as 3 Mb) and a more proximal region between the markers D15S971 and D15S1042 at 15q14 (estimated as 1.1 Mb). Analysis of a panel of 33 bladder tumor cell lines revealed regions of contiguous homozygosity for markers in 15q15, indicating likely LOH. Fluorescence in situ hybridization analysis demonstrated that mitotic recombination is the predicted mechanism of LOH in two of these. These regions of LOH on 15q may contain tumor suppressor genes the loss or inactivation of which is associated with TCC development. The DNA repair gene RAD51 at 15q15.1 represents a candidate 15q tumor suppressor gene. Expression analysis of rad51 protein in tumor cell lines revealed variable levels of expression but no significant loss of expression in cell lines with likely 15q LOH.

This article has been cited by other articles:

				Q. Lan, L. Zhang, M. Shen, W. J. Jo, R. Vermeulen, G. Li, C. Vulpe, S. Lim, X. Ren, S. M. Rappaport, et al. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity Carcinogenesis, January 1, 2009; 30(1): 50 - 58. [Abstract] [Full Text] [PDF]

				R. Vuononvirta, N. J. Sebire, A. R. Dallosso, J. S. Reis-Filho, R. D. Williams, A. Mackay, K. Fenwick, A. Grigoriadis, A. Ashworth, K. Pritchard-Jones, et al. Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7635 - 7644. [Abstract] [Full Text] [PDF]

				K.-W. Chang, C.-J. Liu, T.-H. Chu, H.-W. Cheng, P.-S. Hung, W.-Y. Hu, and S.-C. Lin Association between High miR-211 microRNA Expression and the Poor Prognosis of Oral Carcinoma Journal of Dental Research, November 1, 2008; 87(11): 1063 - 1068. [Abstract] [Full Text] [PDF]

				R Natrajan, W Warren, B Messahel, J S Reis-Filho, M-A Brundler, J S Dome, P E Grundy, G Vujanic, K Pritchard-Jones, and C Jones Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours J. Clin. Pathol., January 1, 2008; 61(1): 95 - 102. [Abstract] [Full Text] [PDF]

				R. Huijsmans, J. Damen, H. van der Linden, and M. Hermans Single Nucleotide Polymorphism Profiling Assay to Confirm the Identity of Human Tissues J. Mol. Diagn., April 1, 2007; 9(2): 205 - 213. [Abstract] [Full Text] [PDF]

				E. A. Maher, C. Brennan, P. Y. Wen, L. Durso, K. L. Ligon, A. Richardson, D. Khatry, B. Feng, R. Sinha, D. N. Louis, et al. Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities Cancer Res., December 1, 2006; 66(23): 11502 - 11513. [Abstract] [Full Text] [PDF]

				V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516. [Abstract] [Full Text] [PDF]

				C.-C. Chang, M. Campoli, N. P. Restifo, X. Wang, and S. Ferrone Immune Selection of Hot-Spot {beta}2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy J. Immunol., February 1, 2005; 174(3): 1462 - 1471. [Abstract] [Full Text] [PDF]

				J. Adams, S. V. Williams, J. S. Aveyard, and M. A. Knowles Loss of Heterozygosity Analysis and DNA Copy Number Measurement on 8p in Bladder Cancer Reveals Two Mechanisms of Allelic Loss Cancer Res., January 1, 2005; 65(1): 66 - 75. [Abstract] [Full Text] [PDF]

				Y.-S. Jou, C.-S. Lee, Y.-H. Chang, C.-F. Hsiao, C.-F. Chen, C.-C. Chao, L. S.H. Wu, S.-H. Yeh, D.-S. Chen, and P.-J. Chen Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma Cancer Res., May 1, 2004; 64(9): 3030 - 3036. [Abstract] [Full Text] [PDF]